Literature DB >> 17301610

Evolving global risk assessment of ocular hypertension to glaucoma.

Robert D Fechtner1, Albert S Khouri.   

Abstract

PURPOSE OF REVIEW: To discuss current knowledge of global risk assessment in ocular hypertension. RECENT
FINDINGS: The ophthalmologist treating patients with ocular hypertension is frequently faced with the clinical dilemma of which patients to treat and how vigorous treatment should be. The goal of risk assessment for glaucoma is to identify patients at greatest risk for symptomatic vision loss. Risk factors can be identified by history such as age, race, and family history or can be clinically observed by examination such as elevated intraocular pressure, optic nerve head appearance, central corneal thickness, and visual field abnormalities. Risk assessment is a well accepted tool in other fields of medicine. Parallels can be drawn between the evolution of risk assessment for coronary artery disease and glaucoma. Validated risk calculators for ocular hypertension are currently available mostly derived from the Ocular Hypertension Treatment Study.
SUMMARY: The aim of assessing global risk for conversion from ocular hypertension to glaucoma is to identify patients who are most likely to benefit from early treatment. Calculation of risk should be accompanied by thorough analysis of risks, benefits, and alternatives for the individual patient.

Entities:  

Mesh:

Year:  2007        PMID: 17301610     DOI: 10.1097/ICU.0b013e32808373a2

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  4 in total

1.  Brinzolamide/timolol: in open-angle glaucoma and ocular hypertension.

Authors:  Jamie D Croxtall; Lesley J Scott
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

2.  Association between a SLC23A2 gene variation, plasma vitamin C levels, and risk of glaucoma in a Mediterranean population.

Authors:  Vicente Zanon-Moreno; Lucia Ciancotti-Olivares; Jeronimo Asencio; Pedro Sanz; Carolina Ortega-Azorin; Maria D Pinazo-Duran; Dolores Corella
Journal:  Mol Vis       Date:  2011-11-17       Impact factor: 2.367

3.  Smoking, an additional risk factor in elder women with primary open-angle glaucoma.

Authors:  Vicente Zanon-Moreno; Jose J Garcia-Medina; Vicente Zanon-Viguer; Maria A Moreno-Nadal; Maria D Pinazo-Duran
Journal:  Mol Vis       Date:  2009-12-31       Impact factor: 2.367

4.  Selective laser trabeculoplasty: Does energy dosage predict response?

Authors:  Larissa Habib; James Lin; Tamara Berezina; Bart Holland; Robert D Fechtner; Albert S Khouri
Journal:  Oman J Ophthalmol       Date:  2013-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.